• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Cir Cir . Acute kidney injury and mortality in patients with critical COVID-19 in Mexico: case-control study

tetano

Editor, Senior Moderator
Cir Cir


. 2024;92(5):626-632.
doi: 10.24875/CIRU.23000207. Acute kidney injury and mortality in patients with critical COVID-19 in Mexico: case-control study

Ivette Mata-Maqueda[SUP] 1 2 [/SUP], Juan C Solís-Sáinz[SUP] 2 [/SUP], Guadalupe Zaldivar-Lelo de Larrea[SUP] 2 [/SUP], Ernesto Deloya-Tomas[SUP] 1 2 3 [/SUP], Jorge López-Fermín[SUP] 1 2 3 [/SUP], Mª Guadalupe Olvera-Ramos[SUP] 1 2 3 [/SUP], Gabriela Castillo-Gutiérrez[SUP] 1 2 3 [/SUP], Jorge D Carrión-Moya[SUP] 1 2 3 [/SUP], Orlando R Pérez-Nieto[SUP] 1 2 3 [/SUP]



Affiliations
Abstract

in English, Spanish
Objective: We aimed to test the association between acute kidney injury (AKI) and mortality in critically ill patients with Coronavirus disease 2019 (COVID-19).
Method: We conducted a single-center case-control study at the intensive care unit (ICU) of a second-level hospital in Mexico. We included 100 patients with critical COVID-19 from January to December 2021, and collected demographic characteristics, comorbidities, APACHE II, SOFA, NEWS2, and CO-RADS scores at admission, incidence of intrahospital complications, length of hospital and ICU stay, and duration of mechanical ventilation, among others.
Results: The median survival of deceased patients was 20 days. After multivariable logistic regression, the following variables were significantly associated to mortality: AKI (adjusted odds ratio [AOR] 6.64, 95% confidence intervals [CI] = 2.1-20.6, p = 0.001), age > 55 years (AOR 5.3, 95% CI = 1.5-18.1, p = 0.007), and arrhythmias (AOR 5.15, 95% CI = 1.3-19.2, p = 0.015). Median survival was shorter in patients with AKI (15 vs. 22 days, p = 0.043), as well as in patients with overweight/obesity (15 vs. 25 days, p = 0.026).
Conclusion: Our findings show that the development of AKI was the main risk factor associated with mortality in critical COVID-19 patients, while other factors such as older age and cardiac arrhythmias were also associated with this outcome. The management of patients with COVID-19 should include renal function screening and staging on admission to the Emergency Department.

Keywords: Acute kidney injury; COVID-19; Coronavirus disease 2019; Factores de riesgo; Lesión renal aguda; Mortalidad; Mortality; Risk factors; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2.

 
Back
Top Bottom